News

Phase 3 Study of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results

September 23, 2025

DEL MAR, CALIF., USA – CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug Disaggpro^TM (zalunfiban) has shown positive primary efficacy and primary safety outcomes.

Read more

Celecor Completes Multinational Phase 3 Registrational Study of Novel Anti-Platelet Agent for Heart Attack

May 27, 2025

CeleCor Therapeutics has completed its multinational Phase 3 clinical trial of Disaggpro^TM (zalunfiban), an investigational heart-attack drug designed for rapid use at first point of medical contact – including before patients reach the hospital.

Read more

For additional updates including the latest CeleCor news, check out our LinkedIn page.